"A new study finds that women who experience frequent hot flashes in younger midlife (age 40 - 53 years) may be more likely to have poor vascular function regardless of cardiovascular disease (CVD) risk factors or estradiol levels. These findings "...
Serious ill effects have not been reported following acute ingestion of large doses of estrogencontaining drug products by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur in females.
Mimvey (estradiol and norethindrone acetate tablets, USP) should not be used in women with any of the following conditions:
- Undiagnosed abnormal genital bleeding.
- Known, suspected, or history of cancer of the breast.
- Known or suspected estrogen-dependent neoplasia.
- Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
- Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
- Liver dysfunction or disease.
- Known hypersensitivity to the ingredients of estradiol and norethindrone acetate 1 mg/0.5 mg or estradiol and norethindrone acetate 0.5 mg/0.1 mg.
- Known or suspected pregnancy. There is no indication for estradiol and norethindrone acetate in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See PRECAUTIONS.)
Last reviewed on RxList: 4/1/2014
Additional Mimvey Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.